New molecular mutation found in breast tumors
Volume 1, Issue 1, 2012
Edith A. Perez, M.D.
Researchers at Mayo Clinic Cancer Center in Florida have discovered a new class of molecular mutation in various forms of breast cancer. The discovery may shed light on the development and growth of different types of breast tumors. The mutated forms of RNA, called fusion transcripts, may also provide a way to identify tumor subtypes and offer new strategies to treat them.
Their study, published in the April 15 issue of Cancer Research, is the first to systematically search for fusion genes and fusion transcripts linked to different types of breast tumors.
"Oncologists currently recognize three basic types of breast tumors — estrogen receptor (ER) positive, HER2 positive and triple negative," said senior investigator Edith A. Perez, M.D., deputy director at large of the Mayo Clinic Cancer Center, director of the center's Breast Cancer Translational Genomics Program and the Serene M. and Frances C. Durling Professor. "But breast cancer is much more complex than indicated by these three subtypes, and one of the challenges of treating the disease is to identify gene markers that predict how a tumor will respond to a specific treatment."
The discovery of subtype-specific fusion transcripts in breast cancer represents a step in this direction, Dr. Perez said. "Our findings indicate that fusion transcripts are much more common in breast cancer than had been realized. They represent a new class of mutation whose role in breast cancer is not understood at all."
Once the fusion transcripts are better understood, though, the findings could lead to an improved understanding of breast cancer.
"Fusion transcripts have the power to produce proteins that are relevant to tumor development, growth and sensitivity to treatment, so we may have a brand-new set of genomic changes that may help us understand and treat breast cancer in a new way," said E. Aubrey Thompson, Ph.D., professor of biology at Mayo Clinic Cancer Center in Florida and co-director of the Breast Cancer Translational Genomics Program.
"This is a novel discovery that will now require additional investigation," he said. "We need to understand what these fusion transcripts and proteins are doing."
Fusion transcripts are created when chromosomes break apart and recombine, an event that commonly occurs in cancer cells. During this process, fusion genes are created when two halves of normal genes become linked. Fusion genes, or DNA, create fusion transcripts, or RNA, which then produce fusion proteins.
"Mistakes are made," Dr. Thompson said. "That is one of the salient properties of tumor cells, because they are defective in repairing damage to their genes. These mutated proteins may have an entirely new, cancer-promoting function, or they may interfere with normal cellular functions."
Fusion transcripts are common in blood cancers, such as leukemia and lymphoma. Before this discovery, however, few were found in solid cancers such as breast tumors.
Because fusion genes, transcripts and proteins are generally found only in tumors, they make ideal biomarkers to identify tumor cells, Dr. Perez said.
Also, proteins produced by fusion transcripts may be relevant to tumor growth, as has been seen in blood cancers and in lung cancer, she said.
"These transcripts may mark regions of localized chromosomal instability that are linked to growth of breast cancer. If we can develop drugs against these transcripts, they will be ideal therapeutic targets," Dr. Perez said. "We have a lot of exciting work to do in the next few years."
The study was supported in part by grants from the state of Florida Bankhead-Coley Cancer Research Program, the Breast Cancer Research Foundation, 26.2 with Donna, the Carmichael Family Foundation, the Eveleigh Family, the National Cancer Institute and the Mayo Foundation. For information about cancer clinical trials at Mayo Clinic, call 507-538-7623.
Mayo Clinic Breast Cancer Study Finds New Type of Mutation
Watch a video of Dr. Perez discussing this study.